Companies › Cellenkos
3 active drug programs in 3 registered trials: 3 Phase 1; Neurology, Oncology, Other; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CK0804 Cryopreserved allogeneic T-regulatory cell product engineered to traffic to bone marrow | – | Phase 1 | Myelofibrosis | Apr 2027 |
| CK0803 Allogeneic, cord blood-derived T regulatory cells with neurotropic homing markers | – | Phase 1 | Amyotrophic Lateral Sclerosis | May 2027 |
| CK0801 Cord blood-derived T-regulatory cell product | – | Phase 1 | Bone Marrow Disease | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05423691 | CK0804 | Phase 1 | Myelofibrosis | Oncology | Apr 2027 |
| NCT05695521 | CK0803 | Phase 1 | Amyotrophic Lateral Sclerosis | Neurology | May 2027 |
| NCT03773393 | CK0801 | Phase 1 | Bone Marrow Disease | Other | May 2027 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.